The Animal-Free Capital Shift
−7.7%
since Oct 1
The idea
I believe AI is turning animal exploitation into a priced risk, pushing capital away from animal-dependent systems and toward biotech, biomaterials and animal-free infrastructure over the coming decade. The basket spreads evenly across four layers: AI platforms that simulate biology, animal-free biomaterials and lab inputs, drug development moving off animal testing, and fermentation-based or plant protein replacing animal agriculture. Larger, steadier names anchor each layer while earlier-stage ones stay small, with a small cash buffer held aside.
What it owns
- Labs and factories are quietly swapping animal-derived reagents and materials for recombinant and synthetic ones, driven by cost rather than ethics. · RepligenIt makes animal-free bioprocessing inputs like recombinant Protein A, replacing components once harvested from animals., Twist BioscienceIt prints synthetic DNA, a core input for building biology without animals., AvantorIt supplies lab reagents and consumables at scale, capturing the shift as labs swap animal-derived inputs like fetal bovine serum for animal-free ones., CodexisIt engineers enzymes that replace animal-derived catalysts and inputs in manufacturing.25%
- The compute and modeling platforms that make simulating biology cheaper than using animals, which is the core mechanism of this take. · NVIDIAIt sells the compute that makes simulating biology cheaper than exploiting it, the enabling layer for the entire take., Tempus AIIt turns clinical data into training material for AI models of human biology, which lets drug testing lean less on animals., AlphabetIt owns DeepMind and Isomorphic Labs, the AlphaFold lineage that made simulated biology credible as a foundation for this take.25%
- Food is the largest animal-dependent system, and these companies build the ingredients and fermentation capacity that substitute for it. · International Flavors & FragrancesIt supplies the fermentation and flavor ingredients that make animal-free food taste right and compete with animal-based products., Ginkgo BioworksIt engineers organisms for fermentation, building the machinery for making proteins without animals., IngredionIt supplies plant proteins and specialty starches to food makers, earning whenever a product swaps an animal input for a plant one., OatlyIt is the consumer-facing test of this take, winning only if people actually shift spending from dairy to plant-based alternatives.21%
- Regulatory agencies are phasing out animal testing requirements, and these companies sell the simulations and AI models that replace it. · CertaraIt sells the biosimulation software regulators already accept, so it anchors drug development moving off animal testing as the FDA phases it out., SchrödingerIt designs drugs by simulating molecular physics, embodying the premise that simulating biology gets cheaper than exploiting it., Recursion PharmaceuticalsIt builds AI maps of biology to find drugs without the traditional animal-heavy pipeline., AbsciIt designs antibodies with AI instead of harvesting them from animals, a direct animal-free replacement in drug development.19%
- Cash11%